Osteoclastic expression of higher-level regulators NFATc1 and BCL6 in medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis

Table 2 Descriptive data

	Group	Min	Max	Mean	Median	IQR	SD
Anti-NFATc1 staining
Nuclear expression
NFATc1 + osteoclasts per ROI (osteoclasts/mm²)	MRONJ (BP)	0.0	171.7	31.2	25.1	45.9	36.1
	OM	0.0	31.4	7.0	0.0	14.1	9.8
	ORN	0.0	36.5	11.4	1.8	22.3	13.8
	CONTROL	0.0	5.8	0.8	0.0	0.6	1.9
Labeling index (%/100)	MRONJ (BP)	0	1	0.569	0.573	0.790	0.381
	OM	0	1	0.304	0	0.650	0.396
	ORN	0	1	0.424	0.248	1	0.440
	CONTROL	0	0.420	0.065	0	0.060	0.144
Anti-BCL6 staining
Cytoplasmic expression
BCL6 + osteoclasts per ROI (osteoclasts/mm²)	MRONJ (BP)	0.0	113.1	33.2	29.1	29.4	25.9
	OM	0.0	43.4	11.4	9.2	16.5	12.4
	ORN	0.0	141.3	19.7	5.6	13.6	35.8
	CONTROL	0.0	9.2	1.7	0.0	3.5	3.1
Labeling index (%/100)	MRONJ (BP)	0	1	0.760	0.860	0.380	0.300
	OM	0	1	0.445	0.444	0.860	0.391
	ORN	0	1	0.714	0.839	0.560	0.349
	CONTROL	0	0.370	0.100	0	0.300	0.163
Nuclear expression
BCL6 + osteoclasts per ROI (osteoclasts/mm²)	MRONJ (BP)	0	73.4	17.6	13.1	21.4	16.9
	OM	0	11.4	2.9	2.1	4.1	3.7
	ORN	0	92.5	10.8	2.5	10.4	23.4
	CONTROL	0	9.3	1.9	0	4.0	3.3
Labeling index (%/100)	MRONJ (BP)	0	1	0.469	0.483	0.58	0.329
	OM	0	0.72	0.160	0.075	0.29	0.218
	ORN	0	1	0.416	0.282	0.46	0.342
	CONTROL	0	0.56	0.109	0	0.27	0.189
Nuclear BCL6 + osteoclasts to cytoplasmic BCL6 + osteoclasts (%/100)	MRONJ (BP)	0	1	0.513	0.503	0.433	0.308
	OM	0	0.450	0.164	0.127	0.355	0.177
	ORN	0	0.778	0.460	0.500	0.333	0.237
	CONTROL	0	1	0.243	0	0.550	0.424

Min minimum, Max maximum, IQR interquartile range, SD standard deviation, ROI region of interest, MRONJ (BP) medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy, OM osteomyelitis, ORN osteoradionecrosis, NFATc1 nuclear factor of activated T-cells, cytoplasmic 1, BCL6 B-cell lymphoma 6

ISSN: 1479-5876